BB Biotech AG (BION) - Total Assets
Based on the latest financial reports, BB Biotech AG (BION) holds total assets worth CHF2.64 Billion CHF (≈ $3.34 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore BB Biotech AG cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
BB Biotech AG - Total Assets Trend (2003–2025)
This chart illustrates how BB Biotech AG's total assets have evolved over time, based on quarterly financial data. See BION total equity for net asset value and shareholders' equity analysis.
BB Biotech AG - Asset Composition Analysis
Current Asset Composition (December 2025)
BB Biotech AG's total assets of CHF2.64 Billion consist of 3.8% current assets and 96.2% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 3.5% |
| Accounts Receivable | CHF5.51 Million | 0.2% |
| Inventory | CHF0.00 | 0.0% |
| Property, Plant & Equipment | CHF0.00 | 0.0% |
| Intangible Assets | CHF0.00 | 0.0% |
| Goodwill | CHF0.00 | 0.0% |
Asset Composition Trend (2003–2025)
This chart illustrates how BB Biotech AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of BB Biotech AG.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BB Biotech AG's current assets represent 3.8% of total assets in 2025, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 3.5% of total assets in 2025, up from 0.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
BB Biotech AG Competitors by Total Assets
Key competitors of BB Biotech AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
BB Biotech AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 758.29 | 8.40 | 13.95 |
| Quick Ratio | 758.29 | 8.40 | 13.95 |
| Cash Ratio | 0.89 | 0.00 | 0.00 |
| Working Capital | CHF1.84 Billion | CHF2.39 Billion | CHF3.23 Billion |
BB Biotech AG - Advanced Valuation Insights
This section examines the relationship between BB Biotech AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.94 |
| Latest Market Cap to Assets Ratio | 0.89 |
| Asset Growth Rate (YoY) | 15.7% |
| Total Assets | CHF2.79 Billion |
| Market Capitalization | $2.48 Billion USD |
Valuation Analysis
Near Book Valuation: The market values BB Biotech AG's assets close to their book value (0.89x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: BB Biotech AG's assets grew by 15.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BB Biotech AG (2003–2025)
The table below shows the annual total assets of BB Biotech AG from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CHF2.79 Billion ≈ $3.52 Billion |
+15.72% |
| 2024-12-31 | CHF2.41 Billion ≈ $3.04 Billion |
-8.71% |
| 2023-12-31 | CHF2.64 Billion ≈ $3.33 Billion |
-13.63% |
| 2022-12-31 | CHF3.05 Billion ≈ $3.86 Billion |
-16.21% |
| 2021-12-31 | CHF3.64 Billion ≈ $4.61 Billion |
-8.05% |
| 2020-12-31 | CHF3.96 Billion ≈ $5.01 Billion |
+11.49% |
| 2019-12-31 | CHF3.55 Billion ≈ $4.49 Billion |
+15.15% |
| 2018-12-31 | CHF3.09 Billion ≈ $3.90 Billion |
-15.15% |
| 2017-12-31 | CHF3.64 Billion ≈ $4.60 Billion |
+12.76% |
| 2016-12-31 | CHF3.23 Billion ≈ $4.08 Billion |
-22.14% |
| 2015-12-31 | CHF4.14 Billion ≈ $5.24 Billion |
+17.29% |
| 2014-12-31 | CHF3.53 Billion ≈ $4.47 Billion |
+59.79% |
| 2013-12-31 | CHF2.21 Billion ≈ $2.80 Billion |
+60.91% |
| 2012-12-31 | CHF1.37 Billion ≈ $1.74 Billion |
+19.31% |
| 2011-12-31 | CHF1.15 Billion ≈ $1.46 Billion |
-16.37% |
| 2010-12-31 | CHF1.38 Billion ≈ $1.74 Billion |
-9.46% |
| 2009-12-31 | CHF1.52 Billion ≈ $1.92 Billion |
-6.07% |
| 2008-12-31 | CHF1.62 Billion ≈ $2.05 Billion |
-22.04% |
| 2007-12-31 | CHF2.08 Billion ≈ $2.63 Billion |
-18.67% |
| 2006-12-31 | CHF2.55 Billion ≈ $3.23 Billion |
+2.22% |
| 2005-12-31 | CHF2.50 Billion ≈ $3.16 Billion |
+30.25% |
| 2004-12-31 | CHF1.92 Billion ≈ $2.42 Billion |
-3.26% |
| 2003-12-31 | CHF1.98 Billion ≈ $2.51 Billion |
-- |
About BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domicile… Read more